NCT04234022

Zn-DDC to Target Hypoxia-NFkappaB-CSCs Pathway and Improve the Treatment Outcomes of Haematological Malignancies - A Translation Bench Study

Recruiting now Last updated 8 April 2026

What this trial tests

trial testing Zn-DDC in Multiple Myeloma in 70 participants. Currently enrolling.

Timeline

22 October 2021

Primary endpoint
1 December 2027

1 December 2027

Quick facts

Lead sponsor	The Royal Wolverhampton Hospitals NHS Trust
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	70
Start date	22 October 2021
Primary completion	1 December 2027
Estimated completion	1 December 2027
Sites	1 location across United Kingdom

Drugs / interventions tested

• Zn-DDC — full drug profile →
• Lanalidomide with Zn-DDC — full drug profile →
• Pomalidomide with Zn-DDC — full drug profile →

Conditions studied

• Multiple Myeloma — all drugs for Multiple Myeloma →

Sponsor

The Royal Wolverhampton Hospitals NHS Trust

Who can join

18 and older, any sex, with Multiple Myeloma. Patients with the condition only — healthy volunteers not accepted.

What's being measured

Primary outcomes are the specific endpoints the trial is designed to prove or disprove.

• Imuthiol and zinc efficacy
  Time frame: 7 days
  examine the cyctotoxicity of Imuthiol and zinc in combination with other drugs
• Cell kill and determination of IC50 (inhibitory concentration) and apoptotic pathways involved
  Time frame: 7 days
  Cell kill and determination of IC50 (inhibitory concentration) and apoptotic pathways involved

Sponsor's own description

The outlook for patients with haematological malignancies remains challenging. It has been shown in some early cancer studies that a particular drug called Zn-DDC otherwise known as Imuthiol is highly toxic to cancer stem cells. Imuthiol has been intravenously used in clinical trials with an excellent safety record. Recent novel therapy and immunotherapy in haematological malignancies have improved outcome and survival but come with an increasing cost burden. Imuthiol could be an ideal affordable drug to study on it's own as well as in combination with other drugs in myeloma and other haematological malignancies. This may lead to potential combination therapies which will be very effective as well as affordable in the future. There is the need to look to see if this drug, Imuthiol and along with complementary drugs lenalidomide (Revlimid) and pomalidomide (Pomalyst) can help in haematological malignancy treatment. In order to do this there is the need to see how the cancer cells respond to the drugs in the laboratory before being able to trial the drug (or combination of drugs) out for treatment. The success of this study may lead to quick translation of Imuthiol into haematological malignancy treatment.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

1. Crosstalk between endoplasmic reticulum stress and oxidative stress: a dynamic duo in multiple myeloma.
   Xiong S, Chng WJ, Zhou J. · · 2021 · cited 61× · PMID 33599798 · DOI 10.1007/s00018-021-03756-3
2. Can NF-κB Be Considered a Valid Drug Target in Neoplastic Diseases? Our Point of View.
   Labbozzetta M, Notarbartolo M, Poma P. · · 2020 · cited 38× · PMID 32349210 · DOI 10.3390/ijms21093070
3. The revival of dithiocarbamates: from pesticides to innovative medical treatments.
   Kaul L, Süss R, Zannettino A, Richter K. · · 2021 · cited 34× · PMID 33598645 · DOI 10.1016/j.isci.2021.102092
4. <i>In vitro</i> and <i>in vivo</i> evaluation of diethyldithiocarbamate with copper ions and its liposomal formulation for the treatment of <i>Staphylococcus aureus</i> and <i>Staphylococcus epidermidis</i> biofilms.
   Kaul L, Abdo AI, Coenye T, Swift S, et al · · 2023 · cited 2× · PMID 37274173 · DOI 10.1016/j.bioflm.2023.100130